Enzymatic lacto-N-biose elongation of human milk oligosaccharides with the GH136 lacto-N-biosidase LnbX engineered for improved transglycosylation
Enzyme and Microbial Technology · 2025
DOI: 10.1016/j.enzmictec.2025.110660 ↗Kurz gefasst
Fachartikel in der Zeitschrift Enzyme and Microbial Technology, 2025. Verfasst von Marlene Vuillemin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology and Biomedicine, Technical University of Denmark, Søltofts Plads 221, Kgs. Lyngby 2800 , Denmark. Hauptthemen laut MEDLINE: Milk, Human, Oligosaccharides, Glycoside Hydrolases, Bacterial Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innovation Fund Denmark.
Abstract (Originalsprache)
The lacto-N-biosidase (EC 3.2.1.140) LnbX from Bifidobacterium longum subsp. longum JCM 1217, a member of the glycoside hydrolase family 136 (GH136), was used for single-step lacto-N-biose (LNB) elongation of human milk oligosaccharides (HMOs) via disaccharide transglycosylation to expand the portfolio of HMOs available from enzymatic synthesis. We used the commercially available HMOs lacto-N-tetraose (LNT) as donor and lacto-N-neotetraose (LNnT) as acceptor for the synthesis of para-lacto-N-hexaose (pLNH). To improve the transglycosylation performance of LnbX (18 % molar yield), we designed 14 single mutants using two different strategies: 1) conservative substitution of conserved residues in the active site, and 2) shielding of the active site by large, hydrophobic residues. Protein engineering improved pLNH yield 1.5-fold as compared to the wild type (to 27 %). More than a 3-fold increase was obtained when optimizing the reaction conditions using the best variant, LnbX D416N, by an experimental design including reaction temperature, pH, donor substrate concentration, acceptor-to-donor (A/D) ratio, and enzyme concentration. Higher LNT concentrations and A/D ratios led to increased pLNH yields, and a high A/D ratio also increased the proportion of pLNH among the reaction products. The maximum molar yield of 57 % was obtained after 3 h of reaction at 100 mM LNT, 500 mM LNnT, 1 μM enzyme, 35 °C and pH 6.5. The LnbX D416N enzyme, which can use lacto-N-fucopentaose III (LNFP-III) as an alternative acceptor substrate, is active and stable at industrially relevant ranges of pH and temperature. The enzyme may thus be useful for diversification of the industrially available HMO portfolio.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biotechnology and Biomedicine, Technical University of Denmark, Søltofts Plads 221, Kgs. Lyngby 2800 , Denmark.
- DSM-Firmenich, Kogle Allé 4, Hørsholm 2970, Denmark.
- Department of Biotechnology and Biomedicine, Technical University of Denmark, Søltofts Plads 221, Kgs. Lyngby 2800 , Denmark. Electronic address: bzeu@dtu.dk.
Förderung
- Innovation Fund Denmark
Zitieren
APA
Vuillemin, M., Lengyel, M., Muschiol, J., Matwiejuk, M., Zhang, Y., Cannac, N., Molnar-Gabor, D., Meyer, A. S., & Zeuner, B. (2025). Enzymatic lacto-N-biose elongation of human milk oligosaccharides with the GH136 lacto-N-biosidase LnbX engineered for improved transglycosylation. Enzyme and Microbial Technology. https://doi.org/10.1016/j.enzmictec.2025.110660
Vancouver
Vuillemin M, Lengyel M, Muschiol J, Matwiejuk M, Zhang Y, Cannac N, et al. Enzymatic lacto-N-biose elongation of human milk oligosaccharides with the GH136 lacto-N-biosidase LnbX engineered for improved transglycosylation. Enzyme and Microbial Technology. 2025. doi:10.1016/j.enzmictec.2025.110660
BibTeX
@article{Vuillemin2025,
author = {Vuillemin, Marlene and Lengyel, Marton and Muschiol, Jan and Matwiejuk, Martin and Zhang, Yan and Cannac, Nathan and Molnar-Gabor, Dora and Meyer, Anne S and Zeuner, Birgitte},
title = {Enzymatic lacto-N-biose elongation of human milk oligosaccharides with the GH136 lacto-N-biosidase LnbX engineered for improved transglycosylation},
journal = {Enzyme and Microbial Technology},
year = {2025},
doi = {10.1016/j.enzmictec.2025.110660}
}
EUVIMED